<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03833336</url>
  </required_header>
  <id_info>
    <org_study_id>PREFER-HF</org_study_id>
    <secondary_id>2016-003604-31</secondary_id>
    <nct_id>NCT03833336</nct_id>
  </id_info>
  <brief_title>Effects of Iron Therapy in Heart Failure With Preserved Ejection Fraction and Iron Deficiency (PREFER-HF)</brief_title>
  <acronym>PREFER-HF</acronym>
  <official_title>Effects of Intravenous Iron Therapy With Ferric Carboxymaltose Compared With Oral Iron Therapy in Heart Failure With Preserved Ejection Fraction and Iron Deficiency (PREFER-HF)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut de Recerca Biomèdica de Lleida</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fundació La Marató de TV3</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Institut de Recerca Biomèdica de Lleida</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate whether the administration of iron to patients with&#xD;
      heart failure and preserved ejection fraction results in an improvement of symptoms and&#xD;
      functional class, in addition to evaluating whether oral iron is equivalent to intravenous&#xD;
      iron to achieve this improvement.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Iron deficiency is one of the most prevalent co-morbid conditions in chronic heart failure.&#xD;
      In the absence of any iron treatment, it is estimated that up to 50% of patients with heart&#xD;
      failure have low levels of available iron. Treatment with intravenous iron improves exercise&#xD;
      tolerance , quality of life , and reduces hospitalization in patients with chronic heart&#xD;
      failure and reduced ejection fraction. However data on the effect of iron therapy in patients&#xD;
      with heart failure with preserved ejection fraction are still lacking. The evidence related&#xD;
      to oral iron therapy in HF is limited and no randomized trials compared oral iron vs no iron&#xD;
      therapy in the absence of erythropoiesis-stimulating agents.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">August 23, 2017</start_date>
  <completion_date type="Anticipated">June 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Six minute walking test distance</measure>
    <time_frame>24 weeks</time_frame>
    <description>Change in meters traveled in six minute walking test from baseline to week 24. An increase in distance is related to an improvement in functional capacity.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in New York Heart Association (NYHA) functional classification</measure>
    <time_frame>24 weeks</time_frame>
    <description>Change in New York Heart Association functional classification (I-IV) from baseline to week 24. A decrease is related to an improvement in functional capacity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life assesed by Kansas City Cardiomyopathy Questionnaire</measure>
    <time_frame>24 weeks</time_frame>
    <description>Change in Minnesota Living with Heart Failure questionnaire (0-100) from baseline to week 24. Questionnaire is s a 23-item, self-administered instrument that quantifies physical function, symptoms (frequency, severity and recent change), social function, self-efficacy and knowledge, and quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalizations</measure>
    <time_frame>24 weeks</time_frame>
    <description>Rate of any, HF-related or other cardiovascular hospitalizations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>24 weeks</time_frame>
    <description>All causes and cardiovascular mortality</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">72</enrollment>
  <condition>Heart Failure With Normal Ejection Fraction</condition>
  <condition>Ferropenic Anemia</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>normal saline solution plus oral lactose capsules</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intravenous ferric carboxymaltose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ferric carboxymaltose 500-1000 mg at 0,6,12,24 weeks ( adjusted by protocol)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oral iron A: ferroglycine sulfate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>oral capsules of ferroglycine sulfate iron until week 24</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oral iron B: sucrosomial iron</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>oral capsules of sucrosomial iron until week 24</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>The group assigned to placebo will receive an infusion of normal saline solution plus oral lactose capsules identical to oral medication.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ferric carboxymaltose</intervention_name>
    <description>The group assigned to receive intravenous iron will receive intravenous ferric carboxymaltose ajusted by weight and Hb levels according to study protocol plus oral placebo</description>
    <arm_group_label>Intravenous ferric carboxymaltose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ferroglycine Sulfate</intervention_name>
    <description>One group assigned to receive oral iron will receive two 100 mg oral capsule of ferroglycine sulfate plus intravenous placebo (normal saline solution)</description>
    <arm_group_label>Oral iron A: ferroglycine sulfate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sucrosomial Iron</intervention_name>
    <description>One group assigned to receive oral iron will receive or two oral capsule containing 30 mg of pyrophosphate sucrosomial iron plus intravenous placebo (normal saline solution)</description>
    <arm_group_label>Oral iron B: sucrosomial iron</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects with stable chronic HF (NYHA II/IV functional class) on optimal background&#xD;
             therapy (as determined by the investigator) for at least 4 weeks with no dose changes&#xD;
             of heart failure drugs during the last 2 weeks (with the exception of diuretics). In&#xD;
             general, optimal pharmacological treatment should include an angiotensin-converting&#xD;
             enzyme inhibitor or angiotensin II receptor blocker and a beta blocker unless&#xD;
             contraindicated or not tolerated and diuretic if indicated.&#xD;
&#xD;
          -  Left ventricular ejection fraction &gt;45% (value within 3 months of planned date of&#xD;
             randomization).&#xD;
&#xD;
          -  BNP &gt;100 pg/mL and/or N-terminal-pro-BNP &gt;400 pg/mL at the screening visit.&#xD;
&#xD;
          -  Subject must be capable of completing the 6 minute walking test&#xD;
&#xD;
          -  Screening serum ferritin &lt;100 ng/mL or 100-300 ng/mL with transferrin saturation &lt;20%.&#xD;
&#xD;
          -  At least 18 years of age.&#xD;
&#xD;
          -  Before any study-specific procedure, the appropriate written informed consent must be&#xD;
             obtained.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subject has known sensitivity to any of the products to be administered during dosing.&#xD;
&#xD;
          -  History of acquired iron overload.&#xD;
&#xD;
          -  History of erythropoietin-stimulating agent, i.v. iron therapy, and/or blood&#xD;
             transfusion in previous 6 weeks prior torandomization.&#xD;
&#xD;
          -  Oral iron therapy at doses &gt;100 mg/day in previous 1 week prior to randomization.&#xD;
             Note: ongoing use of multivitamins containing iron &lt;75 mg/day is permitted.&#xD;
&#xD;
          -  Exercise training programme(s) in the 3 months prior to screening or planned in the&#xD;
             next 6 months.&#xD;
&#xD;
          -  Known active bacterial infection.&#xD;
&#xD;
          -  Chronic liver disease (including active hepatitis) and/or screening alanine&#xD;
             transaminase or aspartate transaminase above three times the upper limit of the normal&#xD;
             range.&#xD;
&#xD;
          -  Subjects with known hepatitis B surface antigen positivity and/or hepatitis C virus&#xD;
             ribonucleic acid positivity.&#xD;
&#xD;
          -  Vitamin B12 and/or serum folate deficiency. If deficiency-corrected subject may be&#xD;
             rescreened for inclusion.&#xD;
&#xD;
          -  Subjects with known seropositivity to human immunodeficiency virus.&#xD;
&#xD;
          -  Clinical evidence of current malignancy with exception of basal cell or squamous cell&#xD;
             carcinoma of the skin, and cervical intraepithelial neoplasia.&#xD;
&#xD;
          -  Currently receiving systemic chemotherapy and/or radiotherapy.&#xD;
&#xD;
          -  Renal dialysis (previous, current, or planned within the next 6 months).&#xD;
&#xD;
          -  Unstable angina pectoris as judged by the investigator; severe valvular or left&#xD;
             ventricular outflow obstruction disease needing intervention; atrial&#xD;
             fibrillation/flutter with a mean ventricular response rate at rest &gt;100 beats per&#xD;
             minute.&#xD;
&#xD;
          -  Acute myocardial infarction or acute coronary syndrome, transient ischemic attack, or&#xD;
             stroke within the last 3 months prior to randomization.&#xD;
&#xD;
          -  Coronary artery bypass graft, percutaneous intervention (e.g. cardiac,&#xD;
             cerebrovascular, and aortic; diagnostic catheters are allowed), or major surgery,&#xD;
             including thoracic and cardiac surgery, within the last 3 months prior to&#xD;
             randomization.&#xD;
&#xD;
          -  Subject currently is enrolled in or has not yet completed at least 30 days since&#xD;
             ending other investigational device or drug study(ies), or subject is receiving other&#xD;
             investigational agent(s).&#xD;
&#xD;
          -  Subject of childbearing potential who is pregnant (e.g. positive human chorionic&#xD;
             gonadotropin test) or is breastfeeding.&#xD;
&#xD;
          -  Subject will not be available for all protocol-specified assessments.&#xD;
&#xD;
          -  Subject has any kind of disorder that compromises the ability of the subject to give&#xD;
             written informed consent and/or to comply with study procedures.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jose Luis Morales-Rull, MD,PhD</last_name>
    <phone>0034+616424858</phone>
    <email>jl.moralesrull@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital Universitari Arnau de Vilanova</name>
      <address>
        <city>Lleida</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jose Luis Morales-Rull, MD,PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>February 5, 2019</study_first_submitted>
  <study_first_submitted_qc>February 6, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 7, 2019</study_first_posted>
  <last_update_submitted>February 6, 2019</last_update_submitted>
  <last_update_submitted_qc>February 6, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 8, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Institut de Recerca Biomèdica de Lleida</investigator_affiliation>
    <investigator_full_name>José Luis Morales Rull, MD, PhD</investigator_full_name>
    <investigator_title>José Luis Morales Rull, MD, PhD, Principal Investigator NUTRIMMIC group ( Nutrition Metabolism and Microbiota in Heart Failure)</investigator_title>
  </responsible_party>
  <keyword>heart failure</keyword>
  <keyword>preserved ejection fraction</keyword>
  <keyword>ferropenic anemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Anemia, Iron-Deficiency</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

